Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting
May 26 2022 - 4:05PM
Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”,
a clinical-stage biopharmaceutical company focused on oncology and
rare diseases, today announced the presentation of interim clinical
data from its Phase 1b/2 Study of Etigilimab and Nivolumab in
Subjects with Select Locally Advanced or Metastatic Solid Tumors in
a poster at the 2022 American Society of Clinical Oncology (ASCO)
Annual Meeting taking place June 3 – 7, 2022 in Chicago IL.
“We are very pleased that the interim results
from our ACTIVATE study have been accepted for presentation at
ASCO,” said Dr. Denise Scots-Knight, Chief Executive Officer of
Mereo. “We are encouraged by the results reported as of the cut off
date for the abstract, especially the early efficacy noted in
cervical cancer, where we have seen one patient with a complete
response, one with a partial response and one with stable disease,
as well as the uveal melanoma arm where we saw three patients
achieving stable disease with over 20 weeks of treatment. We
look forward to sharing the updated data in our ASCO presentation
with the oncology community.”
At the time of the February 10, ASCO abstract
deadline, of the 27 efficacy-evaluable subjects with minimum of 1
staging scan or radiological/clinical progression, 12 subjects had
a clinical benefit with 1 CR, 2 PRs and 9 SDs and 15 subjects had
radiological/clinical progression, with an overall response rate
(ORR) of 11% and disease control rate (DCR) of 44%. The combination
of etigilimab and nivolumab has been safe and well tolerated, with
no new safety signals observed to-date.
Details of the data presentation are as
follows:
Abstract Title: A Phase 1b/2
Study of Etigilimab and Nivolumab in Subjects with Select Locally
Advanced or Metastatic Solid Tumors (ACTIVATE)Session Date
& Time: Sunday, June 5 at 9AM ET Session
Title: Developmental
Therapeutics—ImmunotherapyAbstract ID:
2651Poster: 305
About Mereo BioPharmaMereo
BioPharma is a biopharmaceutical company focused on the development
of innovative therapeutics that aim to improve outcomes for
oncology and rare diseases and plans to commercialize selected rare
disease programs. The Company has developed a portfolio of six
clinical stage product candidates. Mereo’s lead oncology product
candidate, etigilimab (anti-TIGIT), has advanced into an open label
Phase 1b/2 basket study evaluating anti-TIGIT in combination with
an anti-PD-1 in a range of tumor types including three rare tumors
and three gynecological carcinomas, cervical, ovarian, and
endometrial carcinomas. The Company’s second oncology product,
navicixizumab, for the treatment of late line ovarian cancer, has
completed a Phase 1 study and has been partnered with OncXerna
Therapeutics, Inc., formerly Oncologie, Inc. The Company has two
rare disease product candidates, alvelestat for the treatment of
severe Alpha-1 antitrypsin deficiency (AATD) and Bronchiolitis
Obliterans Syndrome (BOS), and setrusumab for the treatment of
osteogenesis imperfecta (OI). Alvelestat has received U.S. Orphan
Drug Designation for the treatment of AATD and positive top-line
data were recently reported from a Phase 2 proof-of-concept study
in North America, Europe and the UK. The Company’s partner,
Ultragenyx Pharmaceutical, Inc., has initiated a pivotal Phase 2/3
pediatric study in young adults (5-25 years old) for setrusumab in
OI and expects to initiate a study in pediatric patients (2-5 years
old) in the second half of 2022.
Forward-Looking StatementsThis
press release contains “forward-looking statements.” All statements
other than statements of historical fact contained in this press
release are forward-looking statements within the meaning of
Section 27A of the United States Securities Act of 1933, as amended
(the “Securities Act”), and Section 21E of the United States
Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Forward-looking statements usually relate to future events and
anticipated revenues, earnings, cash flows or other aspects of our
operations or operating results. Forward-looking statements are
often identified by the words “believe,” “expect,” “anticipate,”
“plan,” “intend,” “foresee,” “should,” “would,” “could,” “may,”
“estimate,” “outlook” and similar expressions, including the
negative thereof. The absence of these words, however, does not
mean that the statements are not forward-looking. These
forward-looking statements are based on the Company’s current
expectations, beliefs and assumptions concerning future
developments and business conditions and their potential effect on
the Company. While management believes that these forward-looking
statements are reasonable as and when made, there can be no
assurance that future developments affecting the Company will be
those that it anticipates.
All of the Company’s forward-looking statements
involve known and unknown risks and uncertainties some of which are
significant or beyond its control and assumptions that could cause
actual results to differ materially from the Company’s historical
experience and its present expectations or projections. You should
carefully consider the foregoing factors and the other risks and
uncertainties that affect the Company’s business, including those
described in the “Risk Factors” section of its latest Annual Report
on Form 20-F, reports on Form 6-K and other documents furnished or
filed from time to time by the Company with the Securities and
Exchange Commission. The Company wishes to caution you not to place
undue reliance on any forward-looking statements, which speak only
as of the date hereof. The Company undertakes no obligation to
publicly update or revise any of our forward-looking statements
after the date they are made, whether as a result of new
information, future events or otherwise, except to the extent
required by law.
|
|
Mereo BioPharma
Contacts: |
|
Mereo |
+44 (0)333 023
7300 |
Denise Scots-Knight, Chief
Executive Officer |
|
Christine Fox, Chief Financial
Officer |
|
|
|
Burns McClellan
(Investor Relations Adviser to Mereo) |
+01 212 213
0006 |
Lee Roth |
|
Investors |
investors@mereobiopharma.com |
|
|
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Jul 2023 to Jul 2024